Skip to main content
. 2024 Mar 19;83(6):760–774. doi: 10.1136/ard-2024-225534

Figure 2.

Figure 2

Efficacy results of randomised controlled trials stratified by mode of action and disease domain. Data from previous systematic literature research are also accounted for in this figure. *Different instruments used in studies. ABA, abatacept; ACR, American College of Rheumatology Response; ADA, adalimumab; APR, apremilast; BKZ, bimekizumab; CD, cluster of differentiation; CZP, certolizumab-pegol; ETN, etanercept; GOL, golimumab; GUS, guselkumab; HAQ, Health Assessment Questionnaire Disability Index; IL, interleukin; IFX, infliximab; IXE, ixekizumab; JAK, Janus kinases; PDE4, phosphodiesterase-4; PsA-mSvdHS, Psoriatic Arthritis modified Sharp van der Heijde Score; RIS, risankizumab; SEC, secukinumab; TNF, tumour necrosis factor; TOFA, tofacitinib; UPA, upadacitinib; UST, ustekinumab.